• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Ulcerative colitis (subacute manifestations) - infliximab

Infliximab for the sub-acute manifestations of ulcerative colitis

Status:	History
Expected date of issue:	April 2008
Wave:	13
Process:	STA
Topic area: Digestive system

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Peter Littlejohns
Technical Lead:	Rodrigo Refoios Camejo
Communications manager:	Kristin O'Leary
Project manager:	Eloise Saile
Evidence review group:	West Midlands Health Technology Assessment Collaboration

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	25 May 2007
Final scope published:	March 2007
1st appraisal committee meeting:	22 August 2007
2nd appraisal committee meeting	20 November 2007

Top

 

Consultees and commentators

Consultees Commentators (no right of appeal) Manufacturers / Sponsors Schering-Plough Ltd (infliximab) Patient / Carer Groups Colostomy Association National Association for Colitis and Crohn 's Disease (NACC) Ostomy Lifestyle Centre Professional Groups Association of Coloproctology of Great Britain and Ireland Primary Care Society for Gastroenterology RoyalCollegeof Anaesthetists RoyalCollegeof General Practitioners Royal College of Nursing RoyalCollegeof Pathologists RoyalCollegeof Physicians RoyalCollegeof Surgeons Royal Pharmaceutical Society Royal Society of Medicine - Intellectual Disabilities Forum Others Department of Health LutonTeaching PCT Welsh Assembly Government General British National Formulary Department of Health, Social Services and Public Safety for Northern Ireland NHS Quality Improvement Scotland Comparator Manufacturers AAH Pharmaceuticals Ltd (sulfasalazine, azathioprine) Alpharma Ltd (sulfasalazine, azathioprine) Dowelhurst Ltd (sulfasalazine, azathioprine) Dr Falk Pharma UK Ltd (mesalazine) Ferring Pharmaceuticals (UK) (mesalazine) Forest Laboratories UK Ltd (prednisolone ?foam and enema) Generics UK Ltd (sulfasalazine, azathioprine) GlaxoSmithKline (azathioprine, mercaptopurine) IVAX Pharmaceuticals UK Ltd (sulfasalazine, azathioprine, mesalazine) Kent Pharmaceuticals Ltd (sulfasalazine, azathioprine) Novartis Pharmaceuticals UK Ltd (ciclosporin) Meda Pharmaceuticals Ltd (hydrocortizone -foam) Pfizer Ltd (sulfasalazine) Procter & Gamble UK (mesalazine) Shire Pharmaceuticals Limited (balsalazide) Teva UK Ltd (azathioprine) UCB Pharmaceuticals Ltd (olsalazine, prednisolone - enema) Unichem Ltd (sulfasalazine, azathioprine) Evidence Review Groups National Coordinating Centre for Health Technology Assessment West Midlands Health Technology Assessment Collaboration Associated Guideline Groups None Associated Public Health Groups None Research Groups  None

Top

 

Project history

Date Update 16 March 2007 Referred in February 2007 as one of the topics in the 13th wave. 22 March 2007 Final scope, pre-referral scope, response to comments on the scope, pre-referral matrix, response to comments on the Matrix published. 22 March 2007 Final matrix published. (Stakeholders - Commentators and consultees) 7 September 2007 Project Manager changed to Eloise Saile

Top

 

Key documents

Colitis (ulcerative) - infliximab: Final appraisal determination 13 March 2008 Colitis (ulcerative) - infliximab: Consultees and Commentators 10 January 2008 Infliximab for ulcerative colitis (appraisal consultation document) 15 September 2007 Evidence considered 15 September 2007 Infliximab for ulcerative colitis - Final Scope 22 March 2007 Infliximab for ulcerative colitis - Pre-referral Scope 22 March 2007 Infliximab for ulcerative colitis - Response to comments on the Scope 22 March 2007 Infliximab for ulcerative colitis - Pre-referral Matrix 22 March 2007 Infliximab for ulcerative colitis - Response to comments on the Matrix 22 March 2007

This page was last updated: 30 March 2010